Antineoplastics
1
Reactions 1376 - 5 Nov 2011 Antineoplastics Skin toxicity and peripheral neuropathy: case report A 59-year-old man developed skin toxicity and peripheral neuropathy during combination chemotherapy for metastatic colorectal cancer. Following a diagnosis of advanced sigmoid colon cancer with multiple liver metastases, the man began receiving modified FOLFOX6 (fluorouracil, folinic acid [leucovorin] and oxaliplatin) with cetuximab. IV cetuximab 400 mg/m 2 was infused over 120 min on day 1, with subsequent weekly doses of 250 mg/m 2 infused over 60 min, and mFOLFOX6 was administered biweekly, with a reduced dose of oxaliplatin (60 mg/m 2 ) and infusional fluorouracil (1650 mg/m 2 ). He was discharged after 2 cycles, and subsequently received cetuximab 500 mg/m 2 with biweekly mFOLFOX6 on an outpatient basis. After the fourth cycle, the doses of oxaliplatin and fluorouracil were increased to standard doses. After 6 cycles, he developed grade 2 peripheral neuropathy and grade 2 skin toxicity. Oxaliplatin was discontinued due to peripheral neuropathy. The man continued to receive outpatient chemotherapy, with no apparent regrowth of liver metastases. Mizota A, et al. FOLFOX plus cetuximab for a patient with metastatic colorectal cancer with icterus due to multiple liver metastases. Gan to Kagaku Ryoho 38: 1205-1208, No. 7, 6 Jul 2011 - Japan 803062208 1 Reactions 5 Nov 2011 No. 1376 0114-9954/10/1376-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
Transcript of Antineoplastics
Reactions 1376 - 5 Nov 2011
Antineoplastics
Skin toxicity and peripheral neuropathy: casereport
A 59-year-old man developed skin toxicity and peripheralneuropathy during combination chemotherapy formetastatic colorectal cancer.
Following a diagnosis of advanced sigmoid colon cancerwith multiple liver metastases, the man began receivingmodified FOLFOX6 (fluorouracil, folinic acid [leucovorin]and oxaliplatin) with cetuximab. IV cetuximab 400 mg/m2
was infused over 120 min on day 1, with subsequentweekly doses of 250 mg/m2 infused over 60 min, andmFOLFOX6 was administered biweekly, with a reduceddose of oxaliplatin (60 mg/m2) and infusional fluorouracil(1650 mg/m2). He was discharged after 2 cycles, andsubsequently received cetuximab 500 mg/m2 withbiweekly mFOLFOX6 on an outpatient basis. After thefourth cycle, the doses of oxaliplatin and fluorouracil wereincreased to standard doses. After 6 cycles, he developedgrade 2 peripheral neuropathy and grade 2 skin toxicity.
Oxaliplatin was discontinued due to peripheralneuropathy. The man continued to receive outpatientchemotherapy, with no apparent regrowth of livermetastases.Mizota A, et al. FOLFOX plus cetuximab for a patient with metastatic colorectalcancer with icterus due to multiple liver metastases. Gan to Kagaku Ryoho 38:1205-1208, No. 7, 6 Jul 2011 - Japan 803062208
1
Reactions 5 Nov 2011 No. 13760114-9954/10/1376-0001/$14.95 © 2010 Adis Data Information BV. All rights reserved
